8-KLeadership ChangesExhibits & Filings

BIOGEN INC. 8-K Report, Executive Changes (Sep 21, 2020)

Filed September 21, 2020For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on September 21, 2020, reporting the departure of its Executive Vice President and Chief Financial Officer, Jeffrey D. Capello, effective September 15, 2020. Mr. Capello's departure triggers severance benefits in accordance with the company's established executive severance policy. This filing is primarily administrative, confirming the leadership change in the crucial CFO role and outlining the financial arrangements associated with Mr. Capello's exit. In addition to standard severance, the Compensation and Management Development Committee approved a special cash payment of $2.6 million to Mr. Capello. This payment includes a waiver of the requirement for him to repay 35% of his original cash sign-on bonus, acknowledging his past contributions to the company. Investors should note this change in financial leadership and understand that the associated payments are outlined in the filing.

Key Highlights

  • 1Jeffrey D. Capello has departed from his role as Executive Vice President and Chief Financial Officer (CFO) of Biogen Inc.
  • 2Mr. Capello's last day of employment with Biogen was September 15, 2020.
  • 3Upon departure, Mr. Capello is entitled to severance benefits as per Biogen's executive severance policy.
  • 4The Compensation Committee approved a $2.6 million cash payment to Mr. Capello.
  • 5This payment includes a waiver of the repayment of 35% of his original cash sign-on bonus.
  • 6The waiver and additional payment are in recognition of Mr. Capello's contributions to the company.
  • 7The filing does not disclose any specific reasons for Mr. Capello's departure beyond acknowledging his contributions.

Frequently Asked Questions

The 8-K filing states that Jeffrey D. Capello ceased to be the Executive Vice President and Chief Financial Officer and left the company effective September 15, 2020. While the filing acknowledges his contributions, it does not explicitly state the reasons for his departure.

Mr. Capello will receive severance benefits as per Biogen's executive severance policy. Additionally, the Compensation Committee approved a special cash payment of $2.6 million, which includes a waiver of the requirement to repay 35% of his original cash sign-on bonus.

The $2.6 million payment is described as an additional payment approved by the Compensation Committee, partly to waive the repayment of a sign-on bonus, in recognition of his contributions. While severance benefits are also provided under the company policy, this specific cash amount appears to be an additional recognition payment.

A change in CFO can be significant as this role is critical for financial reporting and strategy. Investors should look for information on who will succeed Mr. Capello and the transition plan for the CFO responsibilities to assess any potential impact on the company's financial management and investor relations.